Evidence map›Paper›PMID 35225481›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Anticancer Effects of Urtica Dioica in Breast Cancer.

Percin Karakol, Serpil Unver Saraydin, Mehmet Bozkurt, Ceylan Hepokur, Zeynep Deniz Sahin Inan, Mustafa Turan

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Journal of biomedical physics & engineering · 2026
    Article
  4. Article
  5. Article
  6. Advanced biomedical research · 2025
    Article
  7. Article
  8. Article
  9. International journal of molecular sciences · 2024
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Percin KarakolPlastic Reconstructive and Aesthetic Surgery, Health Science University, Bagcilar Education and Training Hospital, Istanbul, Turkey.ORCID 0000-0003-0068-2139
Serpil Unver SaraydinDepartment of Histology and Embryology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.ORCID 0000-0001-7639-7487
Mehmet BozkurtPlastic Reconstructive and Aesthetic Surgery, Health Science University, Bagcilar Education and Training Hospital, Istanbul, Turkey.ORCID 0000-0002-4480-513X
Ceylan HepokurDepartment of Plastic Surgery, Health Science University, Istanbul, Turkey.ORCID 0000-0001-6397-1291
Zeynep Deniz Sahin InanDepartment of Histology and Embryology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.ORCID 0000-0002-0292-4448
Mustafa TuranDepartment of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey.ORCID 0000-0002-7449-8150.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe goal of this study is to look into the antiproliferative capabilities of Urtica Dioica (UD) on breast cancer.

methodsThe cytotoxicity of UD extracts against breast cancer cell lines was investigated. Flow cytometry analyses were used to investigate in vitro apoptosis of breast cancer cells using Annexin V labeling. In vivo tests also performed.

resultsUD showed cytotoxicity to three cancer cell lines. The number of Annexin-positive cells was higher in UD-treated cell lines than in untreated control cells. When compared to the untreated control group, the rats treated with UD had greater expressions of caspase 3, p53 protein, and TUNEL positive cells. When compared to the control group, Ki-67 expression was reduced in the treatment groups. In vivo tests revealed that, when compared to untreated rats, the mean tumor volume inhibition ratio in the UD group was 38 percent.

conclusionThese findings suggest that Urtica Dioica may have antitumoral properties in the treatment of breast cancer.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCaspase 3Cell Line, TumorDisease Models, AnimalFemaleHumansIn Situ Nick-End LabelingKi-67 AntigenPlant ExtractsRatsTumor Suppressor Protein p53Urtica dioicaAntineoplastic AgentsCaspase 3Ki-67 AntigenPlant ExtractsTumor Suppressor Protein p53Anticancerbreast cancerCytotoxicityIn vitroUrtica dioica

Identifiers

PMID35225481
PMCPMC9272626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.